Full-Time

Scientist

In Vivo Operations

Updated on 9/3/2026

Merge Labs

Merge Labs

11-50 employees

Develops high-bandwidth brain–computer interfaces

Compensation Overview

$120k - $165k/yr

San Francisco, CA, USA

In Person

PhD

Category
Biology & Biotech (1)

Get referred to Merge Labs

See people who can refer or advise you

Requirements
  • A PhD or equivalent experience leading research projects end-to-end in Neuroscience, Biology, Bioengineering, or a related field, with 5+ years of relevant postdoctoral or equivalent industry experience.
  • Hands-on in vivo research experience with strong expertise in rodent brain surgery and a track record of high-quality study execution, attention to detail, and rigorous documentation practices.
  • Proven ability to design and execute end-to-end in vivo studies.
  • Strong understanding of experimental rigor, reproducibility, and data quality.
  • Experience working in fast-paced, cross-functional environments.
  • Experience collaborating and communicating with multidisciplinary experts across disciplines.
Responsibilities
  • Design, execute, and scale high-throughput in vivo neuroscience studies in rodents, focusing on stereotaxic surgeries and delivery methods, while overseeing dosing, monitoring, imaging, endpoint procedures, consistency, precision, and reproducibility.
  • Design, develop, and optimize novel in vivo methodologies.
  • Develop, establish, and characterize novel animal models to evaluate the functionality of engineered proteins.
  • Collaborate with cross-functional teams to develop and refine gene delivery for targeted and efficient expression in the central nervous system.
  • Contribute to custom experimental setups integrating imaging and neuromodulation technologies.
  • Ensure compliance with animal welfare, regulatory, and biosafety standards.
  • Mentor and guide Research Associates to support scaling of in vivo operations.
Desired Qualifications
  • Experience with molecular tools such as optogenetics, chemogenetics, or sonogenetics.
  • Experience with gene delivery.
  • Experience with ultrasound.
  • Experience in immunology.

Merge Labs develops brain–computer interfaces to connect human brains with computers. Its product focus is high-bandwidth neural implants that read neural signals and transmit data to AI systems and software, enabling bidirectional communication between brain and machine. The implants are designed to work with advances in AI and neural sensing hardware, using a system of implants, interfaces, and software to interpret brain activity and control devices or software. Compared with competitors, Merge Labs aligns with Sam Altman’s vision of human–machine convergence, leveraging OpenAI ventures connections and positioning itself as a Neuralink rival with an emphasis on higher data throughput and scalable AI-assisted interpretation. The company’s goal is to create seamless, high-bandwidth brain–computer communication that enhances human capabilities and enables new ways of interacting with technology.

Company Size

11-50

Company Stage

Seed

Total Funding

$252M

Headquarters

Palo Alto, California

Founded

2025

Get referred to Merge Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Butterfly's September 1, 2026 deal creates a commercial supply chain immediately.
  • OpenAI pledged scientific foundation models and frontier tools to accelerate Merge's R&D.
  • Ultrasound BCI leverages Butterfly's 71.4% gross margin platform and semiconductor manufacturing.

What critics are saying

  • A $252 million seed round funds research, not FDA-approved products or revenue.
  • Neuralink's implant-first progress and clinical visibility threaten Merge's noninvasive positioning.
  • OpenAI's insider support invites governance scrutiny if Merge misses milestones before 2027.

What makes Merge Labs unique

  • OpenAI invested in Merge Labs' $252 million seed round at an $850 million valuation.
  • Merge Labs uses ultrasound-on-chip from Butterfly Network, unlike Neuralink's invasive electrodes.
  • Sam Altman, OpenAI, and Forest Neurotech give Merge exceptional AI and neuroscience access.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-8%

2 year growth

-8%
Yahoo Finance
Sep 3rd, 2026
Sam Altman-backed Merge Labs selects Butterfly Network as exclusive ultrasound chip supplier for brain interfaces

Merge Labs, a brain-interface startup backed by OpenAI and Sam Altman, has selected Butterfly Network as its exclusive ultrasound-on-chip supplier under a multiyear agreement. The deal includes upfront payments, development milestones, purchase commitments, access fees, and potential royalties, though specific amounts were not disclosed. Butterfly's semiconductor-based ultrasound architecture makes the system programmable and easier to embed in new devices. The company retained rights to license its technology to other partners. Butterfly's second-quarter revenue increased 39% to $32.6 million, with gross margin expanding to 71.4%. Adjusted EBITDA loss narrowed 78% to $1.4 million. Management raised full-year revenue guidance to $119 million to $123 million. Thirty-three hedge funds held Butterfly Network in the second quarter, up from 26 in the first quarter.

Florida Today
Feb 14th, 2026
OpenAI invests in Merge Labs at $850M valuation

OpenAI has invested in Merge Labs at an $850 million valuation, according to reports. The investment focuses on scalable AI backends, including AICC technology. Details about the funding round, including the investment amount and other participants, were not disclosed. The partnership appears aimed at advancing AI infrastructure and backend capabilities. Merge Labs is working on developing scalable systems to support AI applications. The company's technology is designed to handle the computational demands of modern AI models. The investment represents OpenAI's continued expansion beyond its core business into supporting technologies and infrastructure for artificial intelligence development.

TechCrunch
Jan 16th, 2026
OpenAI invests in Sam Altman’s brain computer interface startup Merge Labs | TechCrunch

Merge Labs is a “research lab” dedicated to “bridging biological and artificial intelligence to maximize human ability.” OpenAI wrote the largest check in Merge Labs' $250 million seed round at an $850 million valuation.

Bloomberg Law
Jan 15th, 2026
Sam Altman's Merge raises $252M to connect human brains to computers

Merge Labs, co-founded by AI billionaire Sam Altman, has raised $252 million to develop devices connecting human brains to computers. The company aims to seamlessly link people and artificial intelligence to "maximise human ability, agency, and experience". The funding reflects growing Silicon Valley interest in brain-computer interfaces as entrepreneurs anticipate a future where AI becomes so advanced that humans may need to augment their brains to keep pace. Similar to how smartphones provide digital access, experimental brain technology is being designed to streamline human interaction with AI systems. The investment underscores the increasing focus on neurotechnology as a key frontier in the race to integrate artificial intelligence into human capabilities.

Wired
Dec 19th, 2025
Sam Altman’s New Brain Venture, Merge Labs, Will Spin Out of a Nonprofit

Merge Labs, a brain-computer interface startup that seeks to read brain activity using ultrasound, is being spun out of Forest Neurotech, a Los Angeles nonprofit.